1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GENFIT
  6. Summary
    GNFT   FR0004163111

GENFIT

(GNFT)
  Report
Real-time Euronext Paris  -  11:35 2022-07-01 am EDT
3.080 EUR   +0.65%
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/22GENFIT : 2021 Extra-Financial Performance Report
PU
06/21European ADRs Rise Sharply in Tuesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
3.098(c) 3.12(c) 3.14(c) 3.06(c) 3.08(c) Last
63 870 35 801 50 417 49 171 30 800 Volume
-1.40% +0.71% +0.64% -2.55% +0.65% Change
More quotes
Estimated financial data (e)
Sales 2022 14,7 M 15,3 M 15,3 M
Net income 2022 -46,4 M -48,3 M -48,3 M
Net cash position 2022 56,2 M 58,5 M 58,5 M
P/E ratio 2022 -3,68x
Yield 2022 -
Sales 2023 41,9 M 43,6 M 43,6 M
Net income 2023 -6,25 M -6,50 M -6,50 M
Net cash position 2023 53,4 M 55,5 M 55,5 M
P/E ratio 2023 -3,38x
Yield 2023 -
Capitalization 153 M 159 M 159 M
EV / Sales 2022 6,59x
EV / Sales 2023 2,38x
Nbr of Employees 122
Free-Float 86,8%
More Financials
Company
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich... 
More about the company
Ratings of GENFIT
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GENFIT
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/22GENFIT : 2021 Extra-Financial Performance Report
PU
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14European ADRs Move Lower in Tuesday Trading
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/09European ADRs Move Lower in Thursday Trading
MT
06/08European ADRs Move Lower in Wednesday Trading
MT
06/07European ADRs Move Higher in Tuesday Trading
MT
06/02European ADRs Nudge Lower in Thursday Trading
MT
06/01European ADRs Move Lower in Wednesday Trading
MT
05/31European ADRs Nudge Higher in Tuesday Trading
MT
05/31GENFIT : Monthly statement on outstanding equity shares and voting rights
CO
05/26GENFIT, May 25, 2022 Combined Shareholders Meeting results
AQ
05/26GENFIT : May 25, 2022 Combined Shareholders Meeting results - Form 6-K
PU
More news
News in other languages on GENFIT
06/29Les ADR européens progressent légèrement dans la négociation de mercredi
06/21Les ADR européens en forte hausse dans les échanges de mardi
06/15Les ADR européens sont en hausse mercredi
06/14Les ADR européens sont en baisse dans les échanges de mardi
06/13Les ADR européens chutent fortement dans les échanges de lundi
More news
Analyst Recommendations on GENFIT
More recommendations
Chart GENFIT
Duration : Period :
GENFIT Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENFIT
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,08 €
Average target price 10,23 €
Spread / Average Target 232%
EPS Revisions
Managers and Directors
Pascal Prigent CEO & EVP-Marketing & Development
Thomas Baetz Chief Financial Officer
Jean-François Mouney Chairman
Dean W. Hum Chief Scientific Officer
Carol L. Addy Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GENFIT-28.64%159
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.60%19 031